Charlottesville, VA– June 7th, 2019 MPSC announced today that it has signed an exclusive relationship with Tomorrow Medical to represent the HeRO products in the Netherlands, Germany, and Belgium. Tomorrow Medical “Tomorrow Medical is delighted to offer HeRO as a part of its mission to extend and improve life and health by early treatment of health risks,” says its founder, Rob de Vroet. “We strive to provide the highest quality service to our customers and patients.” Now available in 26 countries, HeRO is becoming the standard of care in providing actionable information to improve the care for neonatal intensive care patients. In the NICU, sepsis is the leading cause of death after the first three days of life. It is goal of MPSC to aid doctors to identify and treat earlier, when those treatments are most effective. MPSC’s HeRO product applies the concept of “Big Data” to generate meaningful clinical decision support solutions. Medical Predictive Science Corporation is engaged in the development of computational diagnostic and bio-informatic technologies for the healthcare industry. MPSC is committed to saving lives and reducing healthcare expenditures through the development of effective clinical diagnostic and decision support tools. These products use computational diagnostic methods to make the early diagnosis of clinical illness through continuous, non-invasive patient monitoring, and to provide diagnostic information as well as decision support to the physician. HeRO is a trademark of Medical Predictive Science Corporation.
May 20, 2019 - MPSC welcomes CEMSA to our partners representing HeRO in the many and growing number of countries where HeRO is available. We are delighted to have CEMSA as our representative for Mexico. CEMSA is working hard to obtain the necessary clearances for the sale of HeRO into Mexico and hopes to be able to launch HeRO soon.
MPSC is proud to continue supporting the NICU Leadership Forum put on by Synova Associates. At this year's conference in Litchfield, AZ, we had a great time getting to talk with customers, future customers, and all the other wonderful people at the meeting. We are delighted to congratulate Warren Furry for the winning entry in the raffle.
MPSC is proud to announce that we will be exhibiting at the Arab Health 2019 conference in Dubai, UAE. Arab Health is the largest medical conference in the Middle East. MPSC will be displaying their HeRO solution as a part of the Virginia Economic Development Partnership (VEDP) stand. "We have been very fortunate to have the support of the VEDP in our efforts to expand our international presence," said Geoffrey R Alms, PhD, Executive Vice President of MPSC. HeRO has recently been adopted by Sidra Hospital in Doha, Qatar, and King Hamad Hospital in Al Sayh, Bahrain. "We look forward to working with our partners and leading hospitals in the region," said Will King, CEO.
May 18th, 2018, Charlottesville, Virginia – HeRO solo and HeRO duet now offer data export. In an update to the HeRO solo/duet platform, MPSC is proud to announce the availability of data export from the system. "This is in direct response to the voice of our customers," says Dr. Geoffrey Alms, Executive Vice President of Sales and Marketing at MPSC, "All feedback from our customers is evaluated in trying to improve upon our product portfolio." The new option, called "USB Data Export," will be offered as an optional upgrade available immediately on new production units of HeRO solo and HeRO duet. With the option, customers can export the data from the HeRO monitor onto a user supplied USB stick as a text file. This solution was developed in order to allow clinicians, who are interested in doing research incorporating HeRO, a mechanism for collecting the digital data generated by HeRO. Please contact your local representative about the availability of all the HeRO Products.
May 14th, 2018, Charlottesville, Virginia – the Journal Pediatrics has just published two articles about HeRO monitoring. In the first, “Predicting Extubation Outcomes-A Model Incorporating Heart Rate Characteristics Index”, authors Goel, Chakraborty, Watkins, and Banerjee examined HRC as a predictor of extubation outcome in neonatal patients. They found that patients that failed extubations had both higher baseline HeRO Scores as well as higher post-extubation changes in HRC Scores than infants that succeeded extubation. In the second, “Neonatal Intensive Care Unit Length of Stay Reduction by Heart Rate Characteristics Monitoring”, Swanson and co-authors examined length of stay differences between the two arms of the HeRO randomized controlled trial in light of the competing outcome of a mortality benefit. They found HeRO monitored patients to be discharged alive and before the 120th day of life at a higher rate than controls (83.6% versus 80.1%, p=0.01). They also found that among surviving patients with a positive blood culture, HeRO monitored patients were discharged at a 3.2 day lower PMA than controls (p=0.03). “Clinicians face a real challenge in choosing when to extubate a ventilated patient,” commented Dr. Geoffrey Alms, Executive Vice President of Sales and Marketing at MPSC. “Leaving the patient ventilate increases the risk of pneumonia, but pulling the tube out before the patient is ready, resulting in re-intubation, results in its own set of morbidities. Any role that HeRO can play in helping the clinicians choose the right time to extubate will greatly benefit patients.” Turning to the length of stay publication, Alms commented, “Length of stay in the NICU is a surrogate for cost. So, reducing length of stay is not only good for patients and families, but good for hospitals as well.” He added, [...]
MPSC is proud to have played a part in the care of the Waldrop sextuplets in Huntsville, Alabama. "When we heard that Huntsville Hospital was about to have sextuplets join them, we knew we had to help," says Geoff Alms, Executive Vice President. "Within a week of learning about the pending arrival, we were able to deliver 6 new HeRO Solos ready for use." The family has a Facebook page dedicated to their nine beautiful children and TLC will be hosting a documentary airing Fall 2018.
Charlottesville, VA. As MPSC continues to improve the HeRO product portfolio, we are proud to announce that MPSC has received a substantially equivalent notification regarding its most recent 510k submission, the summary of which is available at https://www.accessdata.fda.gov/cdrh_docs/pdf18/K180242.pdf.
November 29, 2017 - MPSC wants to thank the Virginia Economic Development Partnership (@YesVirginia_org) for the opportunity to exhibit as a proud Virginia based company. "Medica is a key congress to explore business opportunities throughout the world," said Geoffrey Alms, Executive Vice President. "We enjoyed meeting with our current and future partners to bring HeRO to more NICU patients. Medica has been an important part of the expansion of HeRO into many new markets."
Charlottesville, VA– June 20th, 2017 MPSC announced today that it signed the Patient Safety Movement’s Open Data Pledge, a public pledge to share its data to promote patient safety. The Open Data Pledge is designed to foster a marketplace of data analytics to encourage entrepreneurs to develop novel uses of health data that will improve patient safety and reduce preventable deaths. If enough medical technology companies share the data their products generate, it allows engineers and researchers to develop predictive algorithms that notify clinicians and patients of dangerous trends, such as MPSC’s HeRO product. The pledge does not ask any company to share protected or proprietary data or not follow all the privacy laws. To date, 80 companies have made the pledge: http://patientsafetymovement.org/commitments/medical-technology-company-pledges. “Our HeRO Product line proves that the idea of sharing data among device makers and entrepreneurs results in saved lives,” said Will King, CEO. “We look forward to working closely with the Patient Safety Movement Foundation to further the goal of eliminating preventable patient deaths.” More than 3,000,000 people worldwide, and 200,000+ people in the United States die every year in hospitals in ways that could have been prevented. It is the 3rd leading cause of death in the US and the cost is close to $1.44 Trillion. If every Very Low Birth Weight baby in the US were monitored by HeRO, 1,200 additional lives could be saved while simultaneously reducing costs and length of stay. The Patient Safety Movement Foundation is a non-profit that is working with all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. Their mission and public commitment is to eliminate preventable patient deaths by the year 2020. Their annual World Patient Safety, [...]
At the recently concluded Pediatric Academics Society Annual Conference in San Francisco, there were multiple abstracts presented about the HeRO System. Please take a look at these new studies: Sepsis screening in very low birth weight infants using heart rate characteristics monitor. Schibler K, Moreira D. PAS Conference Abstract (2017). Reduced NICU Length of Stay Using Heart Rate Characteristics Monitoring. Swanson, JR, King W, Carlo W, Sinkin RA, Schelonka R, Porcelli PJ, Navarrete C, Bancalari E, Aschner JL, Perez J, Palmer C, O'Shea M, Walker W. PAS Conference Abstract (2017). Cost Analysis of Heart Rate Characteristics Monitoring in the NICU. Karvonen KL, Vergales J, Sinkin RA, Swanson JR. PAS Conference Abstract (2017).
MPSC is proud to continue supporting the NICU Leadership Forum put on by Synova Associates. At this year's conference in Litchfield, AZ, we had a great time getting to talk with customers, future customers, and all the other great nurses at the meeting. The Wigwam Resort, Litchfield AZ
Dr. Keith Barrington has a great blog about neonatal research at Neonatal Research. A recent post talks about the importance of how you present long term outcomes statistics to parents on this post.
Come see us at the NeoHeart: Cardiovascular Management of the Neonate conference at the Manchester Grand Hyatt, San Diego, CA. At this conference, Will King, CEO of MPSC, will be a member of a panel. We're delighted to have this opportunity to be a part of this conference.
Welcome to HeRO. Please enjoy this video overview of the HeRO product.
NICU Technology at Timpanogos Regional Hospital
MPSC is delighted to recognize Meditech as the newest distributor for the HeRO System. Meditech, located in Kingston, Jamaica, has placed a HeRO duet unit into the University Hospital of the West Indies. In addition, we will be presenting HeRO at the 15th Caribbean Neurosciences Symposium. This conference is being held in Montego Bay, Jamaica, from the 26th to the 29th of January.
MPSC is proud to continue building upon the HeRO presence in the international markets. HeRO will be shown at booth Z6.F46 as a part of the US International Pavilion at the Arab Health 2017 conference in Dubai. We look forward to meeting with our established distributors and distributors for additional markets to discuss strategy and to explore beneficial opportunities with our partners. Please come and visit us in Za'abeel Hall 6, stand Z6.F46 while attending the conference.
We anticipate a great opportunity to meet with our dealers and prospective dealers at the upcoming MEDICA 2016 conference in Dusseldorf, Germany. This conference is the one place and time when we can meet with dealers for much of the world all at one place. This year, MPSC will be a part of the USA CEO pavilion in Hall 16, Booth 16C04. We look forward to productive discussions towards expanding the usage of HeRO into new markets, both in Europe and beyond.
MPSC looks forward to attending the Miami Neonatology conference put on by the University of Miami. This is a great event to meet with customers in the area, and there is usually a high attendance by clinicians from South America. We enjoy the high caliber faculty who present at this wonderful conference and expect to have plenty of time to interact with our users.
In honor of September 13 being World Sepsis Day, we want to share some important information about this life threatening condition which affects all too many people. Improving the treatment of sepsis has two facets. First, prevention is key. Frequent handwashing has been proven to reduce the rate of sepsis in the healthcare environment. Second, early identification has a significant impact upon survival and decreases long term morbidities associated with surviving sepsis. The World Sepsis Foundation has lots of very useful information about how you can make a difference. Especially on World Sepsis Day, please take a look at their website and consider a donation. The CDC has recently started their Vital Signs campaign, #vitalsigns, to remind us of the practices that healthcare workers can implement to reduce the impact of this life threatening complication. They have prepared a useful booklet that summarizes what you should do.
In the August 2016 issue of Neonatology today, the University of California San Diego talks about the addition of HeRO to their unit. Read for More.
Increase your knowledge about this life threatening condition. World Sepsis Day is September 13, 2016. For more information, read up at World-Sepsis-Day.org. From their website, "The best centres, mainly in industrialized countries, have doubled patients’ chances of survival, simply by recognising the condition and responding rapidly."
MPSC is excited to support and attend the 43rd Annual Newborn Day at Charleston Area Medical Center. This annual event will be held May 12 - 13 at the Charleston Embassy Suites Hotel.
MPSC is proud to have exhibited at the recently concluded NICU Leadership conference in Jacksonville, FL. The conversations with customers and potential customers demonstrates that the HeRO product continues to gain interest and attract new opportunities.
Building upon our great experiences at the NEO conferences in the past, MPSC will be returning to the NEO 2016 conference to be held at the Hilton Orlando Bonnet Creek. We look forward to meeting with our current and future HeRO users at this highly regarded conference.
MPSC is proud to showcase HeRO at the recent Arab Health 2016 conference. With our growing presence in the region, attending the premier conference was an appropriate venue to increase the awareness of HeRO. We look forward to continuing or growing our relationships in the region.
Methodist Women's Hospital of Omaha, NE, has garnered the attention of the media with their adoption of the HeRO System. Click to see the television news report.
MPSC is proud to announce that the University of California San Diego has added the HeRO Symphony System to their NICU.
Methodist Women's Hospital of Omaha, Nebraska, has chosen to deploy the HeRO System as a part of their update and expansion to the NICU. Read a news article about the expansion here.
MPSC is pleased to announce that Wishaw General Hospital in Scotland has outfitted their entire NICU with the HeRO Monitoring System. Purchased through a donation by Garreth Wood and his wife, former Miss Scotland Nicola Wood, the hospital is the first in Scotland to fully outfit the NICU with HeRO. The BBC has produced a report on the project at: Donation of HeRO on the BBC "MPSC's HeRO System continues to gain new customers across the world," says Will King, CEO of MPSC, "We are delighted that neonatologists choose to place their confidence in our products, adopting them at an increasing rate." About HeRO HeRO® is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient's heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded. In a long-running randomized study of over 3,000 preterm infants, those whose care included the HeRO monitor, experienced greater than 20 percent reduced mortality, effectively saving one infant’s life for every 48 who were monitored. About MPSC MPSC is an entrepreneurial medical device company that translates ICU research discoveries to the patient’s bedside. The company develops predictive technology that detects imminent, catastrophic illness. MPSC’s HeRO monitor is the first of a line of products to monitor in-hospital patients.
MPSC wants to thank Synova Associates for putting on a great conference with the NICU Leadership forum in Palm Springs, CA.
MPSC is pleased to return to the March of Dimes 2015 Conference for Health Professionals to be held at the Hotel Irvine on March 16th and 17th, 2015. This conference focuses on the improvement of neonatal outcomes. MPSC's HeRO products have been shown to decrease mortality by over 20% in a randomized, controlled trial.
For the first time, MPSC will be attending the Gravens Conference from March 3rd-7th at the Sheraton Sand Key Resort in Clearwater Beach, Florida. MPSC is proud to attend this conference focused on the Physical and Developmental Environment of the High Risk Infant.
At the upcoming Cool Topics 2015 conference held at the Coronado Marriott Resort, MPSC will be exhibiting the HeRO range of products with the HeRO duet on display. Please come and visit at the important educational event.
MPSC is proud to return to the NEO Conference put on by Pediatrix at the Bonnet Creek Hilton in Orlando, Florida. MPSC will be displaying the HeRO duet and will be available to discuss the entire range of HeRO products. This conference will be held February 19-21, 2015.
MPSC is proud to sponsor the Neonatal Ventilation Workshop presented in association with The Kingdom of Bahrain Ministry of Health and Arabian Gulf University. This workshop will be held February 5th-8th, 2015 at the Arabian Gulf University.
MPSC is proud to join our local representatives, Infamed, at the Advances in Neonatal-Perinatal Medicine CME course in Philadelphia, Pennsylvania. This educational meeting is being hosted by the highly regarded Children's Hospital of Philadelphia. MPSC will be demonstrating the standalone HeRO duet monitor. Please come and speak with us.
MPSC was proud to exhibit the HeRO duet monitor at the Florida Association of Neonatal Nurse Practitioner's Conference held at the Sheraton Sand Key Resort October 14-18 in Clearwater Beach, Florida. We were delighted to join our local representatives, Bimeco Group, to demonstrate the HeRO System at this educational conference.
Dr. Karen Fairchild* from the University of Virginia will be presenting "Heart Rate and Cardiorespiratory Analysis for Early Detection of NEC" at the 2nd International Conference on NEC: SIGNEC UK held on Sept 3rd & 4th, 2014 in London. *Dr. Fairchild is not a paid representative of MPSC nor has any other conflict of interest with HeRO or MPSC, the producer of HeRO.
Medical Predictive Science Corporation has broadened its portfolio of life-saving neonatal monitors with HeRO Solo – a turnkey single patient HeRO monitor. HeRO monitors detect early signs of distress in NICU patients, commonly caused by infection and other potentially life-threatening illnesses. In the largest randomized controlled trial ever published among NICU patients, HeRO monitoring reduced mortality by 22%. Charlottesville, Va. (PRWEB), May 28, 2014 – Medical Predictive Science Corporation announced the immediate release for sale of HeRO Solo, the latest product in the life-saving line of HeRO NICU patient monitoring devices. “Standing alongside HeRO Symphony, HeRO ES, and HeRO Duet, we now fill out our product portfolio with HeRO Solo,” remarked CEO Will King. He added, “HeRO Solo provides our customers the same life-saving algorithm present in all HeRO products, now in a form factor that simplifies installation and clinical usage to the maximum possible extent.” HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient’s heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded. HeRO monitoring was extensively tested in the largest randomized controlled trial of neonatal patients ever published. In that landmark study, mortality was reduced by 22% percent among those premature infants that received HeRO monitoring, compared with those that did not. “HeRO Solo will reach a new clinical audience. We expect widespread adoption both outside the US where networking infrastructure in the NICU is less prevalent, as well as inside the US where the move to single bed rooms necessitates [...]
17 March 2014 - ITV news speaks with Dr. Banerjee about HeRO from Singleton Hospital in Wales. http://www.itv.com/news/wales/story/2014-03-17/new-technology-could-save-premature-babies-lives/.
MPSC is pleased to welcome Singleton Hospital in Wales to the growing family of HeRO users. We are very proud to work with our partner, SLE Ltd, which represents MPSC in the United Kingdom. SLE helped the customer to successfully receive an innovation grant to deploy the HeRO System in their NICU.
A trio of new publications regarding HeRO hits the press. HeRO Publications lists the HeRO bibliography.
Further evidence of the effectiveness of HeRO is published in the Journal of Clinical Monitoring: Complex signals bioinformatics: evaluation of heart rate characteristics monitoring as a novel risk marker for neonatal sepsis.
Pallets of HeRO duets awaiting international pickup.
HeRO is now Multi-lingual! In response to the increasing demand for HeRO outside of the US, HeRO is now available supporting French, Italian, Russian, and Turkish. Look for more languages to be supported soon!